Adicet Bio (NASDAQ:ACET – Get Free Report) is expected to issue its quarterly earnings data before the market opens on Tuesday, March 18th. Analysts expect the company to announce earnings of ($0.36) per share for the quarter.
Adicet Bio (NASDAQ:ACET – Get Free Report) last issued its earnings results on Thursday, March 6th. The company reported ($0.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.37) by $0.05. On average, analysts expect Adicet Bio to post $-1 EPS for the current fiscal year and $-2 EPS for the next fiscal year.
Adicet Bio Trading Up 0.9 %
Shares of ACET opened at $0.78 on Friday. The business’s 50 day moving average is $0.91 and its 200 day moving average is $1.13. The company has a market capitalization of $64.71 million, a PE ratio of -0.46 and a beta of 1.97. Adicet Bio has a 12-month low of $0.74 and a 12-month high of $2.43.
Analysts Set New Price Targets
Read Our Latest Analysis on Adicet Bio
About Adicet Bio
Adicet Bio, Inc, a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. Its lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma.
Featured Stories
- Five stocks we like better than Adicet Bio
- What is a buyback in stocks? A comprehensive guide for investors
- Ignore Reports, Apple Won’t Install Starlink with iOS 18.3
- CD Calculator: Certificate of Deposit Calculator
- Casey’s Uptrend Remains Strong—New Highs on the Horizon
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- Taiwan Semiconductor’s Huge U.S. Move—Stock Impact Ahead
Receive News & Ratings for Adicet Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adicet Bio and related companies with MarketBeat.com's FREE daily email newsletter.